Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors

#549

Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected with functioning well-differentiated neuroendocrine tumors (NET). There are no studies specifically focusing on NET associated to Multiple Endocrine Neoplasia type 1 (MEN-1).

Aim(s): To evaluate the efficacy of long-acting somatostatin analogues in MEN-1 patients affected with duodeno-pancreatic NET.

Materials and methods: All first-degree relatives of MEN-1 subjects, genetically diagnosed for MEN-1 before the clinical diagnosis of NET and with evidence of one or more duodeno-pancreatic NET <15 mm in size, were enrolled. Twenty-two patients with MEN-1-related duodeno-pancreatic NET (age range 21-42 yrs) were treated with Octreotide LAR (30mg/28 days). Treatment duration ranged 1-7 yrs. At the radiological evaluation (performed by multidetector-row computed tomography and endoscopic ultrasound), multiple duodeno-pancreatic NET (range 1-8), sized 3–14 mm, were detected.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F,

Keywords: duodeno-pancreatic tumor, MEN-1, somatostatin analogues,